

<b>Form PTO-1449</b> U.S. Department of Commerce Patent & Trademark Office  <b>INFORMATION DISCLOSURE STATEMENT</b> <i>(Use several sheets if necessary)</i>				Atty. Docket No. 147/49991		Serial No. TBA	
				Applicants Johannes HEBEBRAND, et al.			
				Filing Date Herewith		Group	
<b>U. S. PATENT DOCUMENTS</b>							
Examiner Initial		Document Number	Date	Name	Class	Sub-Class	Filing Date (if appropriate)
	AA						
<b>FOREIGN PATENT DOCUMENTS</b>							
		Document	Date	Country	Class	Sub-class	Translation Yes   No
	AB	EP0138441	04/1985	Europe			Yes
	AC	WO9800130	01/1998	WO			Yes
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
	AD	Karl M. WILBUR, "Electrometric and Colorimetric Determination of Carbonic Anhydrase" Journal of Biological Chemistry, Vol. 176, 1948					
	AE	Claudia T. SUPURAN, "Carbonic anhydrase inhibitors and their therapeutic potential" Ashley Publications Ltd., pp. 1354-3776, 200					
	AF	MK HELLERSTEIN, "De novo lipogenesis in humans: metabolic and regulatory aspects" European Journal of Clinical Nutrition, 1993					
	AG	Bruce E. MARYANOFF, "Structure-Activity Studies on Anticonvulsant Sugar Sulfamates Related to Topiramate. Enhanced Potency with Cyclic Sulfate Derivatives" J. Med. Chemistry, Vol. 41, pp. 1315-1343, 1998					
	AH	Susanna J. DODGSON, "Topiramate as an Inhibitor of Carbonic Anhydrase Isoenzymes" Epilepsia, Vol. 41, 2000					
	AI	Y. Pocker, J.T. STONE, "The Catalytic Versatility of Erythrocyte Carbonic Anhydrase. The Enzyme-Catalyzed Hydrolysis of p-Nitrophenyl Acetate" Journal of the American Chemistry Society, 87:23, 1965					
	AJ	Robert W. HECK, "Catalytic Properties of Mouse Carbonic Anhydrase V*" The Journal of Biological Chemistry, Vol. 269, No. 40, 1994					
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.							

<b>Form PTO-1449</b> U.S. Department of Commerce Patent & Trademark Office		<b>Atty. Docket No.</b> 147/49991	<b>Serial No.</b> TBA
<b>INFORMATION DISCLOSURE STATEMENT</b> <i>(Use several sheets if necessary)</i>		<b>Applicants</b> Johannes BEBEBRAND, et al.	
		<b>Filing Date</b> Herewith	<b>Group</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	AK	Gautam SANYAL, "Thermodynamics of Carbonic Amhydrase Catalysis" The Journal of Biological Chemistry, Vol. 256, No. 2, 1981	
	AL	James E. P. TOMAN, "Properties of Maximal Seizures, and their Alteration by Anticonvulsant Drugs and other Agents" University of Utah School of Medicine, 1946	
	AM	Y. POCKER, "The Catalytic Versatility of Erythrocyte Carbonic Anhydrase III. Kinetic Studies of the Enzyme-Catalyzed Hydrolysis of p-Nitrophenyl Actate" Biochemistry, Vol. 6, No. 3, 1967	
	AN	Claudia T. SUPURAN, "Carbonic anhydrase inhibitors-Part 53. Synthesis of substituted-pyridinium derivatives of aromatic sulfonamides: The first non-polymeric membrane-impermeable inhibitors with selectivity for isozyme IV" Eur. J. Med. Chemistry, Vol. 33, 1998	
	AO	Graham CHEN, "Evaluation of Five Methods for Testing Anticonvulsant Activities" Department of Pharmacology, Parke, Davis & Co., 1954	
	AP	Andrea SCOZZAFAVA, "Carbonic Anhydrase Inhibitors: Synthesis of Water-Soluble, Aminoacyl/Dipeptidyl Sulfonamides Possessing Long-Lasting Intraocular Pressure-Lowering Properties via the Topical Route" J. Med. Chemistry, Vol. 42, 1992	
	AQ	Raja G. KHALIFAH, "The Carbon Dioxide Hydration Activity of Carbonic Anhydrase" The Journal of Biological Chemistry, Vol. 246, No. 8, 1971	
	AR	Stacy A. HAZEN, "Differentiation-dependent expression of CA V and the role of carbonic anhydrase isozymes in pyruvate carboxylation in adipocytes" The FASEB Journal, 1995	
	AS	Bruce E. MARYANOFF, "Anticonvulsant O-Alkyl Sulfamates. 2,3:4,5-Bis-O-(1-methylethylidene)-B-D-fructopyranose Sulfamate and Related Compounds" American Chemistry Society, 1987	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	
<b>EXAMINER:</b> Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.			

FORM PTO-1449  INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	U.S. Department of Commerce Patent & Trademark Office	Attorney Docket No. 147/49991	Serial No. 09/907, 440
		Applicant: Johannes HEBEBRAND, et al.	
		Filing Date July 18, 2001	Group

U.S. PATENT DOCUMENTS							
Examiner Initial		Document Number	Date	Name	Class	Sub-Class	Filing Date (if appropriate)
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						

FOREIGN PATENT DOCUMENTS							
Examiner Initial		Document Number	Date	Name	Class	Sub-Class	TRANSLATION
	AK						Yes
	AL						No
	AM						
	AN						
	AO						
	AP						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)							
	AQ	Claudiu T. SUPURAN, et al., "Carbonic anhydrase inhibitors and their therapeutic potential" Expert Opinion on Therapeutic Patents, 2000					
	AR	M. K. HELLERSTEIN, et al., "De novo lipogenesis in humans: metabolic and regulatory aspects" European Journal of Clinical Nutrition, 1999					
	AS						

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.	